ÂÜÀòÂÒÂ×

Shailesh Vengurlekar has a strong background in the pharmaceutical industry, with a particular focus on quality control, regulatory affairs, and product development. Shailesh currently holds the position of Senior Vice President of Quality and Regulatory Affairs at LGM Pharma. Prior to this, Shailesh served as Vice President of Pharmaceutical Development at Palatin Tech, where they oversaw the development of Active Pharmaceutical Ingredients (API), drug products, and associated processes. Shailesh also played a key role in establishing a regulatory strategy for a New Drug Application (NDA) submission and managed non-clinical development studies.

Before joining Palatin Tech, Shailesh was a Manager at Ranbaxy Pharmaceuticals, where they played a crucial role in setting up controlled substances systems across multiple sites and implemented a program to monitor training across different divisions.

Earlier in their career, Shailesh worked at ABC Laboratories, Inc as a Manager/Principal Scientist, responsible for project management, method development, and validation, as well as managing the Bioanalytical and Animal Health divisions. Shailesh also gained experience as a Pharmaceutical Scientist at Interx Pharmaceuticals, where they conducted assay development and routine analysis for formulation and development groups.

Shailesh started their career as an Analytical Development Scientist at Goodlass Nerolac Paints Ltd. Overall, Shailesh's work experience spans over several decades and covers various aspects of pharmaceutical development and regulatory affairs.

Shailesh Vengurlekar began their education history by attending the University of Bombay from 1973 to 1979. During this time, they focused on the field of study in Chemistry. Following this, from 1986 to 1991, Shailesh pursued their education at the University of Kansas, where they studied Chemistry and Business. Finally, from 1994 to 1999, they attended the University of Missouri-Columbia, specializing in Analytical Chemistry. No specific degree names are mentioned in the provided information.